U.S. manufacturing push and Q1 2026 results in focus

Amgen Inc. has announced a fresh $300 million U.S. manufacturing investment and reported first?quarter 2026 financial results, highlighting growth in product sales and margins.

Amgen Inc. has moved into the spotlight after announcing an additional $300 million investment in its U.S. manufacturing network and releasing its first?quarter 2026 financial results. The new capital commitment brings the company’s total U.S. manufacturing outlay over the past year to nearly $2 billion, underscoring its focus on domestic capacity and next?generation biologics production. At the same time, Amgen’s latest quarterly figures show continued revenue growth and solid profitability, reinforcing its position as a leading biotech player for U.S. investors.

According to a press release dated May 4, 2026, Amgen plans to allocate the $300 million to expand and modernize its U.S. manufacturing footprint, including advanced technologies and supply?chain resilience for key medicines. The company emphasized that the investment will support a reliable supply of therapies for patients and align with broader U.S. policy goals around onshoring critical drug production. PR Newswire as of May 4, 2026

On the financial side, Amgen reported first?quarter 2026 results on April 24, 2026, with product sales and overall revenue trending higher year?over?year. Earlier filings and third?party summaries indicate that the company’s quarterly revenue rose about 5.8% versus the same quarter of the prior year, while net margin and return on equity remained strong, reflecting disciplined cost management and pricing power in its core franchises. Stock Titan as of April 24, 2026

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Amgen Inc.
• Sector/industry: Biotechnology / Pharmaceuticals
• Headquarters/country: Thousand Oaks, California, United States
• Core markets: United States, Europe, Japan and other developed markets
• Key revenue drivers: Oncology, cardiovascular, inflammation and bone health franchises
• Home exchange/listing venue: Nasdaq (ticker: AMGN)
• Trading currency: U.S. dollar

Amgen Inc.: core business model

Amgen Inc. operates as a global biotechnology company focused on discovering, developing and commercializing innovative human therapeutics. The firm’s business model centers on proprietary biologic platforms and a diversified portfolio of marketed medicines, primarily in oncology, cardiovascular disease, inflammation and bone health. By investing heavily in research and development, Amgen aims to extend the lifecycle of existing products while advancing a pipeline of novel candidates that can address unmet medical needs.

Amgen’s strategy combines internal R&D with targeted acquisitions and collaborations, allowing it to broaden its therapeutic footprint without over?relying on any single indication. The company markets its products through a global commercial infrastructure, with a particularly strong presence in the United States, where it benefits from favorable reimbursement dynamics and a large patient base. This U.S.?centric exposure makes Amgen a relevant name for American retail investors seeking exposure to the biotech sector.

Main revenue and product drivers for Amgen Inc.

Amgen’s revenue is driven by a portfolio of established biologic brands, including therapies for cancer, cardiovascular risk reduction, inflammatory conditions and osteoporosis. These products typically command premium pricing and benefit from long?term treatment regimens, which support recurring sales and relatively predictable cash flows. Recent quarterly filings indicate that product sales have grown steadily, with total revenues rising to about $9.56 billion in the third quarter of 2025 from $8.50 billion a year earlier, reflecting both volume growth and favorable pricing dynamics. Stock Titan as of November 4, 2025

Within this portfolio, oncology and cardiovascular franchises have been key growth engines, supported by label expansions and new indications. Amgen’s ability to maintain high net margins and strong return on equity suggests effective cost control and pricing power, even as the company continues to invest in R&D and manufacturing. The additional $300 million U.S. manufacturing investment announced in May 2026 is expected to further strengthen supply reliability and operational efficiency, which can help protect margins and support long?term revenue growth.

Conclusion

Amgen Inc. is drawing attention from U.S. investors following a fresh $300 million U.S. manufacturing investment and solid first?quarter 2026 financial results. The company’s focus on expanding domestic production capacity aligns with broader policy trends and may enhance supply reliability for its key medicines. At the same time, continued revenue growth and strong profitability metrics suggest that Amgen’s core franchises remain resilient in a competitive biotech landscape.

For U.S. retail investors, Amgen offers exposure to a diversified biotech portfolio with significant domestic sales and a track record of disciplined capital allocation. However, the stock remains sensitive to regulatory developments, pricing pressures and pipeline execution, which can influence both near?term performance and long?term growth prospects. As with any equity, investors should weigh these factors carefully and consider their own risk tolerance before making decisions.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.

en | US0311621009 | AMGEN INC. | boerse | 69298087 | bgmi

Source link

Kelly leads 52 Republicans in rejecting Chinese auto, battery manufacturing in U.S.

U.S. Rep. Mike Kelly (R-PA) recently led 52 of his Republican colleagues in urging the Trump administration against making any trade decisions that would allow Chinese automotive and battery companies to manufacture their products in the United States.

“The U.S. auto industry is reaching a critical inflection point, as global dynamics and shifts in policy create opportunities for heavily subsidized Chinese automakers to gain momentum using non-market tactics,” wrote Rep. Kelly and the lawmakers in an April 30 letter sent to U.S. Treasury Secretary Scott Bessent, U.S. Commerce Secretary Howard Lutnick, and U.S. Trade Ambassador Jamieson Greer.

“If Chinese automotive companies were granted access to manufacture and sell vehicles and batteries in the U.S., we risk decimating U.S. manufacturing, eroding global market share for U.S. auto companies, and leaving consumers and businesses exposed to serious cybersecurity and surveillance threats,” they wrote. “This is not a winning strategy.”

In their letter, which was sent in advance of President Trump’s meeting with Chinese President Xi Jinping on trade matters between the U.S. and China, the members pointed out that Chinese automotive companies have recently accelerated investment in North America and flooded global markets with the long-term goal of dominating market share and controlling automotive manufacturing and supply chains globally. 

Chinese automakers are also heavily subsidized by the Chinese government, creating an unlevel playing field for American automakers, according to their letter.

“We must be clear-eyed about China’s goals in expanding their automotive footprint across the globe. China’s intent is not fair competition, as evident by their actions in other critical sectors,” the members wrote. “They have drastically inflated supply in their domestic auto market through unfair government subsidies and other benefits intended to artificially prop up companies, forcing them to export and expand to foreign markets at below-market prices. 

“China’s goal is not to compete in the U.S. automotive market, but instead to hollow it out and ultimately limit consumer choice to Chinese brands,” they added. “Allowing Chinese automotive and battery companies to manufacture in the U.S. would jeopardize our national security.”

As negotiations with China continue to develop, wrote the members, they urged the administration to reject any attempts by China to establish vehicle and battery manufacturing facilities stateside or in the broader North American market.

Among the lawmakers who joined Rep. Kelly in signing the letter were U.S. Reps. Carol Miller (R-WV), Michael Rulli (R-OH), Troy Balderson (R-OH), Bob Latta (R-OH), John Joyce (R-PA), Brian Fitzpatrick (R-PA), Kat Cammack (R-FL), Ron Estes (R-KS), Andy Barr (R-KY), John Moolenaar (R-MI), Vern Buchanan (R-FL), Ashley Hinson (R-IA), Erin Houchin (R-IN), Buddy Carter (R-GA), Bill Huizenga (R-MI), Darin LaHood (R-IL), Laurel Lee (R-FL), Blake Moore (R-UT), Kevin Hern (R-OK), Pete Stauber (R-MN), Mike Carey (R-OH), and Rudy Yakym (R-IN).

Post navigation

← Previous Article
Next Article →

Source link